Compare Stocks: ORGO, SLN, IRWD, and NVCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRWD Ironwood Pharmaceuticals	$4.27 -5.7%	$4.15	$1.26 ▼ $5.78	$747.71M	0.2	1.90 million shs	1.66 million shs
NVCT Nuvectis Pharma	$21.07 -8.4%	$21.59	$5.55 ▼ $29.27	$750.81M	-0.26	208,933 shs	169,189 shs
ORGO Organogenesis	$1.45 -2.0%	$1.92	$1.34 ▼ $7.08	$190.44M	1.29	634,727 shs	415,614 shs
SLN Silence Therapeutics	$11.51 -6.3%	$12.76	$4.19 ▼ $17.58	$739.97M	1.45	713,285 shs	876,992 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRWD Ironwood Pharmaceuticals	-5.74%	+2.40%	+3.39%	+11.20%	+207.19%
NVCT Nuvectis Pharma	-8.39%	-3.66%	-11.73%	-24.40%	+251.17%
ORGO Organogenesis	-2.03%	+4.32%	-13.17%	-40.33%	-69.54%
SLN Silence Therapeutics	-6.35%	-7.92%	-13.39%	+15.10%	+123.50%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRWD Ironwood Pharmaceuticals	$4.27 -5.7%	$4.15	$1.26 ▼ $5.78	$747.71M	0.2	1.90 million shs	1.66 million shs
NVCT Nuvectis Pharma	$21.07 -8.4%	$21.59	$5.55 ▼ $29.27	$750.81M	-0.26	208,933 shs	169,189 shs
ORGO Organogenesis	$1.45 -2.0%	$1.92	$1.34 ▼ $7.08	$190.44M	1.29	634,727 shs	415,614 shs
SLN Silence Therapeutics	$11.51 -6.3%	$12.76	$4.19 ▼ $17.58	$739.97M	1.45	713,285 shs	876,992 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRWD Ironwood Pharmaceuticals	-5.74%	+2.40%	+3.39%	+11.20%	+207.19%
NVCT Nuvectis Pharma	-8.39%	-3.66%	-11.73%	-24.40%	+251.17%
ORGO Organogenesis	-2.03%	+4.32%	-13.17%	-40.33%	-69.54%
SLN Silence Therapeutics	-6.35%	-7.92%	-13.39%	+15.10%	+123.50%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IRWD Ironwood Pharmaceuticals	2.57	Moderate Buy	$6.23	45.98% Upside
NVCT Nuvectis Pharma	2.80	Moderate Buy	$36.25	72.05% Upside
ORGO Organogenesis	1.67	Reduce	$4.33	198.85% Upside
SLN Silence Therapeutics	2.83	Moderate Buy	$53.50	364.81% Upside

Current Analyst Ratings Breakdown

Latest ORGO, SLN, IRWD, and NVCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/4/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
9/4/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/4/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/1/2026	NVCT Nuvectis Pharma	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$40.00
9/1/2026	NVCT Nuvectis Pharma	Lucid Cap Mkts Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	NVCT Nuvectis Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight
8/21/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C+)
8/21/2026	ORGO Organogenesis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
8/20/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$25.00 ➝ $32.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IRWD Ironwood Pharmaceuticals	$296.15M	2.38	$0.24 per share	17.58	($1.61) per share	-2.65
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.72 per share	N/A
ORGO Organogenesis	$564.17M	0.33	$0.63 per share	2.29	$2.36 per share	0.61
SLN Silence Therapeutics	$615K	1,126.84	N/A	N/A	$1.32 per share	8.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IRWD Ironwood Pharmaceuticals	$24.02M	$0.77	5.55	N/A	N/A	33.36%	-58.38%	34.93%	11/9/2026 (Estimated)
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-184.25%	-105.24%	11/3/2026 (Estimated)
ORGO Organogenesis	$37.03M	-$0.86	N/A	N/A	N/A	-19.94%	-23.89%	-11.13%	11/5/2026 (Estimated)
SLN Silence Therapeutics	-$88.61M	-$1.28	N/A	N/A	N/A	-8,943.86%	-106.94%	-47.99%	11/5/2026 (Estimated)

Latest ORGO, SLN, IRWD, and NVCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	SLN Silence Therapeutics	-$0.1387	-$0.26	-$0.1213	-$0.27	$1.13 million	N/A
8/6/2026	Q2 2026	IRWD Ironwood Pharmaceuticals	$0.32	$0.31	-$0.01	$0.31	$114.84 million	$113.04 million
8/6/2026	Q2 2026	ORGO Organogenesis	-$0.35	-$0.71	-$0.36	-$0.77	$54.27 million	$43.76 million
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
ORGO Organogenesis	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IRWD Ironwood Pharmaceuticals	N/A	6.06	6.06
NVCT Nuvectis Pharma	N/A	1.68	1.68
ORGO Organogenesis	0.07	3.52	3.00
SLN Silence Therapeutics	N/A	7.42	7.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IRWD Ironwood Pharmaceuticals	N/A
NVCT Nuvectis Pharma	96.77%
ORGO Organogenesis	49.57%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
IRWD Ironwood Pharmaceuticals	9.30%
NVCT Nuvectis Pharma	28.55%
ORGO Organogenesis	18.80%
SLN Silence Therapeutics	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IRWD Ironwood Pharmaceuticals	100	165.24 million	149.87 million	Optionable
NVCT Nuvectis Pharma	13	32.64 million	23.32 million	Not Optionable
ORGO Organogenesis	854	128.68 million	104.48 million	Optionable
SLN Silence Therapeutics	88	60.21 million	58.40 million	Not Optionable

ORGO, SLN, IRWD, and NVCT Headlines

Recent News About These Companies

Head to Head Review: Silence Therapeutics (NASDAQ:SLN) versus Ultragenyx Pharmaceutical (NASDAQ:RARE)

29 minutes ago | americanbankingnews.com

Silence Therapeutics (NASDAQ:SLN) Shares Down 8.7% - Time to Sell?

September 23 at 3:39 PM | marketbeat.com

Contrasting Absci (NASDAQ:ABSI) & Silence Therapeutics (NASDAQ:SLN)

September 21 at 6:14 AM | americanbankingnews.com

Silence Therapeutics plc (SLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16, 2026 | seekingalpha.com

Silence Therapeutics (NASDAQ:SLN) Stock Price Down 5.4% - Here's Why

September 15, 2026 | marketbeat.com

Seven Fleet Capital Management LP Sells 96,652 Shares of Silence Therapeutics PLC Sponsored ADR $SLN

September 5, 2026 | marketbeat.com

Silence Therapeutics to Participate in Three September Investor Conferences

September 2, 2026 | cityam.com

Silence Therapeutics (NASDAQ:SLN) Stock Price Up 5.8% - Should You Buy?

September 1, 2026 | marketbeat.com

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 31, 2026 | marketbeat.com

5AM Venture Management LLC Makes New Investment in Silence Therapeutics PLC Sponsored ADR $SLN

August 26, 2026 | marketbeat.com

Silence Therapeutics: Making Some Recent Noise

August 19, 2026 | seekingalpha.com

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs

August 14, 2026 | businesswire.com

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

August 14, 2026 | cityam.com

Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know

August 13, 2026 | zacks.com

Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Silence Therapeutics (SLN)

August 12, 2026 | theglobeandmail.com

Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley

August 12, 2026 | theglobeandmail.com

Analysts Conflicted on These Healthcare Names: Silence Therapeutics (SLN), Hims & Hers Health (HIMS) and Syndax Pharmaceuticals (SNDX)

August 12, 2026 | theglobeandmail.com

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

August 11, 2026 | businesswire.com

Morgan Stanley maintains Overweight rating on Silence Therapeutics

August 11, 2026 | seekingalpha.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera - Slideshow

August 11, 2026 | seekingalpha.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript

August 10, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO, SLN, IRWD, and NVCT Company Descriptions

Ironwood Pharmaceuticals NASDAQ:IRWD

$4.27 -0.26 (-5.74%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$4.26 -0.01 (-0.33%)

As of 05:21 AM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Nuvectis Pharma NASDAQ:NVCT

$21.07 -1.93 (-8.39%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$21.12 +0.04 (+0.21%)

As of 09/23/2026 07:30 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Organogenesis NASDAQ:ORGO

$1.45 -0.03 (-2.03%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.48 +0.03 (+2.07%)

As of 04:14 AM Eastern

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Silence Therapeutics NASDAQ:SLN

$11.51 -0.78 (-6.35%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$11.50 0.00 (-0.04%)

As of 09/23/2026 07:30 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORGO, SLN, IRWD, and NVCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORGO, SLN, IRWD, and NVCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORGO, SLN, IRWD, and NVCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO, SLN, IRWD, and NVCT Company Descriptions

Ironwood Pharmaceuticals NASDAQ:IRWD

Nuvectis Pharma NASDAQ:NVCT

Organogenesis NASDAQ:ORGO

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORGO, SLN, IRWD, and NVCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORGO, SLN, IRWD, and NVCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORGO, SLN, IRWD, and NVCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO, SLN, IRWD, and NVCT Company Descriptions

Ironwood Pharmaceuticals NASDAQ:IRWD

Nuvectis Pharma NASDAQ:NVCT

Organogenesis NASDAQ:ORGO

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools